Search Results for "Constipation"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Constipation. Results 81 to 90 of 92 total matches.
Treatment of Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • Jan 08, 2024 (Issue 1693)
retention, dry mouth, aggravation
of glaucoma, constipation),
hypotension, heart failure,
ventricular ...
Atrial fibrillation (AF) is the most common arrhythmia
in the world. Risk factor modification, anticoagulation,
rhythm control, and rate control are the four pillars
of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines
on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8 doi:10.58347/tml.2024.1693a | Show Introduction Hide Introduction
Nonopioid Drugs for Pain
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022 (Issue 1645)
(e.g., urinary retention, constipation, dry mouth,
blurred vision, memory impairment, confusion ...
Nonopioid drugs can be used in the treatment of
many nociceptive and neuropathic pain conditions.
For severe pain, especially severe chronic cancer
pain, use of opioids may be necessary. Noninvasive
nonpharmacologic treatments, including physical
and psychological therapies, have been shown to
improve pain and function in patients with some
common chronic pain conditions and are unlikely
to cause serious harms. A multimodal approach to
analgesic therapy can increase pain control while
reducing opioid use and adverse effects.
Drugs for Benign Prostatic Hyperplasia
The Medical Letter on Drugs and Therapeutics • May 02, 2022 (Issue 1649)
anticholinergic adverse
effects include dry mouth, nausea, constipation, and
confusion; use of an M3-selective ...
About 60% of men ≥60 years old have clinically
relevant prostatic enlargement due to benign prostatic
hyperplasia (BPH). The goals of treatment are to
decrease lower urinary tract symptoms and to prevent
disease progression and complications such as acute
urinary retention. The American Urologic Association's
guidelines for treatment of BPH were recently updated.
Drugs for Cognitive Loss and Dementia
The Medical Letter on Drugs and Therapeutics • Aug 22, 2022 (Issue 1657)
, muscle
spasms, insomnia, abdominal pain, constipation,
diarrhea, dizziness, abnormal dreams, and skin ...
Alzheimer's disease (AD) is the most common
cause of dementia, but cognitive decline is also
associated with other neurological conditions such
as Parkinson's disease, dementia with Lewy bodies,
vascular dementia, and frontotemporal dementia.
Drugs for Opioid Use Disorder
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
effects of intranasal naloxone were increased blood
pressure, constipation, toothache, muscle spasms ...
Opioid use disorder is a chronic, relapsing disease with
physical and psychiatric components. It is associated
with economic hardship, social isolation, incarceration,
increased rates of blood-borne infections such as HIV
and viral hepatitis, adverse pregnancy outcomes, and
increased mortality. According to the NIH, there were
80,411 deaths involving an opioid in the US in 2021,
more than in any previous year. Several guidelines on
the management of opioid use disorder are available;
all recommend maintenance pharmacotherapy as the
standard of care.
Med Lett Drugs Ther. 2023 Sep 4;65(1684):137-44 doi:10.58347/tml.2023.1684a | Show Introduction Hide Introduction
Drugs for Postmenopausal Osteoporosis
The Medical Letter on Drugs and Therapeutics • Jul 08, 2024 (Issue 1706)
supplements are
generally well tolerated, but they can cause
constipation, intestinal bloating, and gas ...
Pharmacologic treatment is recommended for
postmenopausal women who have bone density
T-scores (standard deviations from normal mean
values in the spine, femoral neck, total hip, or distal
radius) of -2.5 or below, T-scores between -1.0 and
-2.5 with a history of fragility (low-trauma) fracture
of the hip or spine, or T-scores between -1.0 and
-2.5 with a FRAX 10-year probability of ≥3% for hip
fracture or ≥20% for major osteoporotic fracture.
Med Lett Drugs Ther. 2024 Jul 8;66(1706):105-12 doi:10.58347/tml.2024.1706a | Show Introduction Hide Introduction
Comparison Table: Some Oral Antiseizure Medications (online only)
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024 (Issue 1708)
, pyrexia,
lethargy, drooling,
constipation
Abrupt discontinuation
can cause anterograde
amnesia ...
View the Comparison Table: Some Oral Antiseizure Medications
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e133-40 doi:10.58347/tml.2024.1708b | Show Introduction Hide Introduction
Lipid-Lowering Drugs
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022 (Issue 1659)
of
coronary death or nonfatal myocardial infarction
compared to placebo.32
Adverse Effects – Constipation ...
Cholesterol management guidelines from the
American College of Cardiology/American Heart
Association Task Force were last published in 2019.
Drugs for Anxiety Disorders
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
effects (urinary retention, constipation,
dry mouth, blurred vision, memory impairment,
confusion ...
Anxiety disorders (generalized anxiety disorder,
panic disorder, social anxiety disorder, and various
phobias) are the most common form of psychiatric
illness. They can be treated effectively with cognitive
behavioral therapy (CBT) and/or pharmacotherapy.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):121-8 doi:10.58347/tml.2023.1682a | Show Introduction Hide Introduction
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
-site reactions and
constipation are the most common adverse effects
of CGRP antibodies ...
An oral nonopioid analgesic is often sufficient for
acute treatment of mild to moderate migraine pain
without severe nausea or vomiting. A triptan is the
drug of choice for treatment of moderate to severe
migraine in most patients without vascular disease.
Treatment of pain when it is still mild to moderate in
intensity improves headache response and reduces
the risk of recurrence.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):89-96 doi:10.58347/tml.2023.1678a | Show Introduction Hide Introduction